Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
暂无分享,去创建一个
D. de Jong | J. Schellens | J. Beijnen | S. Leijen | D. Pluim | E. van Werkhoven | G. Sonke | S. Marchetti | E. Rosenberg | M. Lee | S. Rose | T. Freshwater | R. van Geel